HARTREE-PARTNERS
Hartree Partners (UK) Limited (“Hartree”), a wholly owned subsidiary of Hartree Partners LP, which is co-owned by its partners and funds managed by Oaktree Capital Management, announced that it has signed an acquisition agreement for a 50% share in Botres Holding GmbH and its subsidiaries (“Botres”). Headquartered in Graz, Austria, Botres is a key supplier of ultra-modern industrial biogas plants and biorefineries in Austria, Czech Republic, Poland, Italy, Spain and Turkey. Through Bio Scraper, its highly efficient biowaste treatment system, Botres covers the entire processing chain from pre-treatment of all types of organic waste to the efficient production of green energy.
Since being founded in 2012, Botres has built numerous biogas plants across Europe and Turkey and serves some of the world’s largest waste management and infrastructure companies. Botres is led by its founders Dr. Stefan Kromus and Dr. Markus Grasmug, who serve as Managing Directors. Jointly, Dr. Kromus and Dr. Grasmug have over 40 years of experience in the design, development, construction, and operation of waste focused biomethane plants.
Hartree is partnering with Botres to develop a European biomethane production business with a focus on Renewable Energy Directive (RED) compliant feedstocks, which will operate under the Botres brand. The business will focus asset development activities in select countries within the EU and will expand into additional countries on an opportunity-led basis.
“We are excited to partner with Botres, whose innovative technology and proven track record in the biogas space make them an excellent partner for our team as we enter the European biomethane production market. This collaboration directly aligns with Hartree's transition to investing in renewable energy solutions and we look forward to playing a role in providing Europe with clean and reliable biomethane,” said Stephen Hendel, Founding Managing Partner of Hartree Partners LP.
Dr. Kromus said, “We are thrilled to embark on this new chapter with Hartree Partners. This partnership presents a significant opportunity to accelerate the growth of our biomethane production business and solidify Botres' position as a leading player in the industry. We are confident that by combining our expertise and resources, we can deliver exceptional results for our stakeholders and contribute meaningfully to Europe's transition towards a more sustainable energy future.”
About Hartree:
Hartree Partners (UK) Limited is a wholly owned subsidiary of Hartree Partners, LP a limited partnership organised under the laws of Delaware and is a global commodities firm actively trading in oil, gas, power, refined products, shipping, metals and equities. Hartree Partners, LP was established more than 25 years ago and is jointly owned by senior management and funds managed by Oaktree.
Hartree has a unique 25+ year track record in proprietary trading and investing in energy markets across the globe. Our asset development experience ranges from VLCCs, oil, gas and power storage, power generation (conventional & renewable), and gas production facilities, as well as oil refining assets in the US. In Europe Hartree is involved in the UK power market through a portfolio of peak power assets, as well as a portfolio of pan-European renewable generation assets. Hartree acquired a deep knowledge base in the operation of these assets through extensive data analytics and has a wealth of experience in structuring transactions for renewable power and managing intermittent load.
About Botres:
Botres Holding/Botres Global GmbH, headquartered in Graz, Austria, is a leading supplier of modern industrial-scale anaerobic digestion biogas technology, covering the entire process chain from pre-treatment of all types of organic waste, manure and other residues to the efficient production of green energy. Botres was founded in 2012 and emerged from technology development at one of the world’s largest and most successful anaerobic digestion plants in Italy.
Over the past years, Botres has built numerous biogas plants in various European countries, Turkey and Australia. Among Botres’ customers are some of the largest waste management and infrastructure companies in the world. With the development of its highly efficient biowaste treatment system (Bio Scraper), Botres is able to treat basically any type of organic waste. In addition, the technological design and process stability of the plants ensure optimized life cycle expenditures.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240306806400/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Regnology Signs an Agreement to Acquire Moody’s Regulatory Reporting & ALM Solutions18.12.2025 10:00:00 CET | Press release
The deal further strengthens Regnology’s global position in Regulatory Reporting and significantly accelerates its expansion into new markets Regnology, a leading provider in regulatory, risk, tax, and finance reporting, as well as supervisory technology, today announced it has signed an exclusive agreement for the acquisition of Moody’s Regulatory Reporting & ALM Solutions business, inclusive of solutions for Basel III compliance, IFRS9 impairment accounting, large bank asset-liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting across more than 50 jurisdictions. By integrating Moody’s regulatory capital and liquidity capabilities with Regnology’s regulatory, risk, and finance offerings, the firm is creating a unified, scalable platform designed to meet the full spectrum of financial regulatory compliance and risk requirements. This combined strength positions Regnology as the partner of choice for financial institutions seeki
Reply Recognized as a Microsoft Azure Expert Managed Services Provider for the Sixth Consecutive Year18.12.2025 10:00:00 CET | Press release
Reply [EXM, STAR: REY] announced today it has been recognized once again as a Microsoft Azure Expert Managed Services Provider (MSP). The renewal reaffirms Reply’s proven expertise and consistent track record in delivering high-quality cloud solutions and services on the Microsoft Azure platform, powered by the deep technical expertise of its specialized companies – Cluster Reply, Solidsoft Reply and Valorem Reply. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218596617/en/ This recognition reflects the ongoing collaboration between Reply - through its companies Cluster Reply, Solidsoft Reply, and Valorem Reply - and Microsoft, supporting shared efforts to deliver value-driven services to enterprise customers. The Azure Expert MSP program is designed by Microsoft to identify and validate partners with proven capabilities in delivering end-to-end Azure services at scale. To qualify, partners must meet a strict set of requ
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 09:00:00 CET | Press release
Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half of study participants treated with zasocitinib achieved clear or almost clear skin (PASI 90), and on average about 30 percent achieved completely clear skin (PASI 100) by week 16 Zasocitinib was generally well-tolerated with a safety profile consistent with previous clinical studies Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at wee
DATROWAY® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy18.12.2025 08:30:00 CET | Press release
Based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s DATROWAY is the first and only medicine to significantly improve overall survival versus chemotherapy in this patient population If approved, DATROWAY could become the standard of care in this setting The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY® (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Produc
Celltrion receives positive CHMP Opinion for SteQeyma™ (ustekinumab biosimilar) autoinjector18.12.2025 03:41:00 CET | Press release
SteQeyma™45mg and 90mg solution for injection via autoinjector (pre-filled pen) receives positive CHMP opinion, which will facilitate subcutaneous administration in patients with plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD)1The new autoinjector option increases convenience, enhances individual patient experience and expands administration options Celltrion, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion of autoinjector of SteQeyma™, a biosimilar to Stelara® (ustekinumab), for the treatment of plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD). The positive CHMP opinion is for SteQeyma autoinjector in 45mg/0.5mL and 90mg/1mL, expanding the currently approved SteQeyma™ presentation, which includes 45mg/0.5mL, 90mg/1mL in a pre-filled syringe and 45mg/0.5mL in a vial for subcutaneous injection, as well as 130mg/26mL concentrate for solution f
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom